(Total Views: 337)
Posted On: 01/17/2020 6:40:43 AM
Post# of 36568
Good way to think about it.
Having said that we should, quite conservatively be at $5 dollars based on NGIO's value(~300M) and Altucell's(~500M) value(approximate value stated per Joe) and using 70M shares. We would be there had it not been for CM and Veneto. Not only selling but Veneto not screwing up the asset transfer in the first place. There would likely have been some increased revenue the back half of 2019.
A significant non dilutive infusion from BP investing in our robust tech for diabetes I and II research would add $2 rather quickly.
Investors(real) need to know this company has the financial backing to not go dark again and get off the OTC.
All the MSO/HMO stuff aside, this is really about AE37 and diabetes research.
IMO.
Having said that we should, quite conservatively be at $5 dollars based on NGIO's value(~300M) and Altucell's(~500M) value(approximate value stated per Joe) and using 70M shares. We would be there had it not been for CM and Veneto. Not only selling but Veneto not screwing up the asset transfer in the first place. There would likely have been some increased revenue the back half of 2019.
A significant non dilutive infusion from BP investing in our robust tech for diabetes I and II research would add $2 rather quickly.
Investors(real) need to know this company has the financial backing to not go dark again and get off the OTC.
All the MSO/HMO stuff aside, this is really about AE37 and diabetes research.
IMO.
(3)
(0)
